-transparent.png){kind=logo}
Despite extensive study, concerns remain about a possible association between long-term postmenopausal hormone treatment--particularly use of combination preparations--and risk of breast cancer. The authors evaluated the use of postmenopausal hormone replacement therapy in relation to breast cancer risk in a large multicenter, population-based case-control study. Women with a new diagnosis of breast cancer were identified through statewide tumor registries in Wisconsin, Massachusetts, Maine, and New Hampshire. Controls were randomly selected from population lists in each state. For this analysis of postmenopausal women, data were available from 3,130 breast cancer cases and 3,698 controls interviewed between 1989 and 1991. Replacement hormone use was not associated with breast cancer risk in women who had ever undergone this treatment (relative risk (RR) = 1.05, 95% confidence interval (CI) 0.93-1.18). Among women who had used replacement hormones for 15 years or more, there was no clear increase in risk, although the small sample size did not preclude the possibility of a modest association (RR = 1.11, 95% CI 0.87-1.43). Risk among women using progestins in combination with estrogens was similar to that in women using estrogens alone. Risk did not vary according to type of menopause, family history of breast cancer, history of benign breast disease, or alcohol intake. These results are consistent with the majority of reports which find no overall increased risk associated with the use of replacement hormones. However, in contrast to several other studies, this study did not find long-term use to be associated with increased risk. These results also do not support a hypothesized effect of combined progestin and estrogen use on the risk of breast cancer.
P A Newcomb, and
M P Longnecker, and
B E Storer, and
R Mittendorf, and
J Baron, and
R W Clapp, and
G Bogdan, and
W C Willett
October 1996,
American journal of epidemiology,
P A Newcomb, and
M P Longnecker, and
B E Storer, and
R Mittendorf, and
J Baron, and
R W Clapp, and
G Bogdan, and
W C Willett
April 2008,
Therapeutische Umschau. Revue therapeutique,
P A Newcomb, and
M P Longnecker, and
B E Storer, and
R Mittendorf, and
J Baron, and
R W Clapp, and
G Bogdan, and
W C Willett
September 2009,
Epidemiology (Cambridge, Mass.),
P A Newcomb, and
M P Longnecker, and
B E Storer, and
R Mittendorf, and
J Baron, and
R W Clapp, and
G Bogdan, and
W C Willett
August 2011,
Oncology reports,
P A Newcomb, and
M P Longnecker, and
B E Storer, and
R Mittendorf, and
J Baron, and
R W Clapp, and
G Bogdan, and
W C Willett
January 1999,
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
P A Newcomb, and
M P Longnecker, and
B E Storer, and
R Mittendorf, and
J Baron, and
R W Clapp, and
G Bogdan, and
W C Willett
April 2003,
Revue medicale de Liege,
P A Newcomb, and
M P Longnecker, and
B E Storer, and
R Mittendorf, and
J Baron, and
R W Clapp, and
G Bogdan, and
W C Willett
March 2008,
Maturitas,
P A Newcomb, and
M P Longnecker, and
B E Storer, and
R Mittendorf, and
J Baron, and
R W Clapp, and
G Bogdan, and
W C Willett
August 2003,
Zhonghua fu chan ke za zhi,
P A Newcomb, and
M P Longnecker, and
B E Storer, and
R Mittendorf, and
J Baron, and
R W Clapp, and
G Bogdan, and
W C Willett
July 2001,
Chang Gung medical journal,
P A Newcomb, and
M P Longnecker, and
B E Storer, and
R Mittendorf, and
J Baron, and
R W Clapp, and
G Bogdan, and
W C Willett
December 2006,
Expert opinion on pharmacotherapy,
